Scarab Genomics Revenue and Competitors

Scarab Genomics, LLC was established in 2002 to commercialize the Clean Genome® Multiple Deletion Series (MDS) E. colí resulting from Dr. Fred Blattner’s research at the University of Wisconsin, Madison. Scarab Genomics has licensed the patented reduced genome technology from Wisconsin Alumni Research Foundation on an exclusive, worldwide basis. Clean Genome® E. colí was bioengineered by deleting over 15% of the K-12 genome. Using synthetic biology methods, a series of precise deletions were made, including the elimination of non-essential genes, recombinogenic and mobile DNA, and cryptic virulent genes. Genome reduction optimizes these E. colí strains for production, providing enhanced genetic stability and improved metabolic efficiency. Clean Genome® E. colí are the strains of choice for a wide spectrum of applications ranging from routine cloning to large scale production of biopharmaceuticals.